Log in

NASDAQ:ATHXAthersys Stock Price, Forecast & News

$2.90
+0.10 (+3.57 %)
(As of 07/9/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.78
Now: $2.90
$2.91
50-Day Range
$1.97
MA: $2.79
$3.20
52-Week Range
$1.13
Now: $2.90
$4.38
Volume3.53 million shs
Average Volume3.78 million shs
Market Capitalization$569.78 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.7
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke; and that is in Phase II clinical study for the treatment of patients with acute myocardial infarction, as well as that has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical need. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases. It also has license and collaboration agreements with RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; the University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
Read More
Athersys logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.97 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATHX
CUSIPN/A
Phone216-431-9900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.63 million
Book Value$0.15 per share

Profitability

Net Income$-44,580,000.00

Miscellaneous

Employees75
Market Cap$569.78 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive ATHX News and Ratings via Email

Sign-up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter.

Athersys (NASDAQ:ATHX) Frequently Asked Questions

How has Athersys' stock been impacted by COVID-19 (Coronavirus)?

Athersys' stock was trading at $1.28 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ATHX shares have increased by 126.6% and is now trading at $2.90. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Athersys?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Athersys.

When is Athersys' next earnings date?

Athersys is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Athersys.

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) announced its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.02. View Athersys' earnings history.

What price target have analysts set for ATHX?

4 brokers have issued twelve-month target prices for Athersys' shares. Their forecasts range from $5.00 to $14.00. On average, they expect Athersys' stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 210.3% from the stock's current price. View analysts' price targets for Athersys.

Has Athersys been receiving favorable news coverage?

Media headlines about ATHX stock have been trending negative this week, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Athersys earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Athersys.

Who are some of Athersys' key competitors?

What other stocks do shareholders of Athersys own?

Who are Athersys' key executives?

Athersys' management team includes the following people:
  • Dr. Gil Van Bokkelen, Co-Founder, Chairman & CEO (Age 58)
  • Mr. William B. J. Lehmann Jr., M.B.A., J.D., MBA, Pres, COO & Sec. (Age 53)
  • Dr. John J. Harrington, Co-Founder, Chief Scientific Officer, Exec. VP & Director (Age 52)
  • Ms. Laura K. Campbell, Sr. VP of Fin. (Age 55)
  • Karen Hunady, Director of Corp. Communications & Investor Relations

What is Athersys' stock symbol?

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

How do I buy shares of Athersys?

Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Athersys' stock price today?

One share of ATHX stock can currently be purchased for approximately $2.90.

How big of a company is Athersys?

Athersys has a market capitalization of $569.78 million and generates $5.63 million in revenue each year. The biopharmaceutical company earns $-44,580,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. Athersys employs 75 workers across the globe.

What is Athersys' official website?

The official website for Athersys is www.athersys.com.

How can I contact Athersys?

Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company can be reached via phone at 216-431-9900 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.